- Home
- H vs INCY Comparison
H vs INCY Comparison
Compare H & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- H
- INCY
- Stock Information
- Founded
- H 1957
- INCY 1991
- Country
- H United States
- INCY United States
- Employees
- H N/A
- INCY N/A
- Industry
- H Hotels/Resorts
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- H Consumer Discretionary
- INCY Health Care
- Exchange
- H Nasdaq
- INCY Nasdaq
- Market Cap
- H 13.9B
- INCY 17.0B
- IPO Year
- H 2009
- INCY 1993
- Fundamental
- Price
- H $152.68
- INCY $106.70
- Analyst Decision
- H Buy
- INCY Buy
- Analyst Count
- H 15
- INCY 19
- Target Price
- H $158.60
- INCY $89.19
- AVG Volume (30 Days)
- H 1.1M
- INCY 2.8M
- Earning Date
- H 11-06-2025
- INCY 10-28-2025
- Dividend Yield
- H 0.38%
- INCY N/A
- EPS Growth
- H N/A
- INCY 3878.02
- EPS
- H N/A
- INCY 5.90
- Revenue
- H $3,339,000,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- H $121.54
- INCY $19.33
- Revenue Next Year
- H $4.88
- INCY $10.47
- P/E Ratio
- H N/A
- INCY $17.86
- Revenue Growth
- H N/A
- INCY 18.09
- 52 Week Low
- H $102.43
- INCY $53.56
- 52 Week High
- H $168.20
- INCY $109.28
- Technical
- Relative Strength Index (RSI)
- H 57.61
- INCY 73.47
- Support Level
- H $134.73
- INCY $91.16
- Resistance Level
- H $158.84
- INCY $109.28
- Average True Range (ATR)
- H 4.81
- INCY 4.59
- MACD
- H 1.13
- INCY 0.63
- Stochastic Oscillator
- H 73.20
- INCY 88.66
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 30 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.